{
    "clinical_study": {
        "@rank": "11695", 
        "acronym": "REMIND", 
        "arm_group": [
            {
                "arm_group_label": "All meds 1x daily use, all but depression, Rx Timer Cap", 
                "arm_group_type": "Experimental", 
                "description": "Individuals that are suboptimally adherent to targeted therapies except antidepressants, whose medications are all intended for once daily use and are randomized to receive the Rx Timer Cap"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, only depression, Rx Timer Cap", 
                "arm_group_type": "Experimental", 
                "description": "Individuals whose only targeted medications are for depression, whose medications are intended for once daily use and are randomized to receive the Rx Timer Cap"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, all but depression, PillMinder", 
                "arm_group_type": "Experimental", 
                "description": "Individuals that are suboptimally adherent to targeted therapies except antidepressants, whose medications are all intended for once daily use and are randomized to receive the PillMinder"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, only depression, PillMinder", 
                "arm_group_type": "Experimental", 
                "description": "Individuals whose only targeted medications are for depression, whose medications are intended for once daily use and are randomized to receive the PillMinder"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, all but depression, Take-N-Slide", 
                "arm_group_type": "Experimental", 
                "description": "Individuals that are suboptimally adherent to targeted therapies except antidepressants, whose medications are all intended for once daily use and are randomized to receive the Take-N-Slide"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, only depression, Take-N-Slide", 
                "arm_group_type": "Experimental", 
                "description": "Individuals whose only targeted medications are for depression, whose medications are intended for once daily use and are randomized to receive the Take-N-Slide"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, all but depression, Control", 
                "arm_group_type": "No Intervention", 
                "description": "Individuals that are suboptimally adherent to targeted therapies except antidepressants, whose medications are all intended for once daily use and are randomized to proceed with usual care"
            }, 
            {
                "arm_group_label": "All meds 1x daily use, only depression, Control", 
                "arm_group_type": "No Intervention", 
                "description": "Individuals whose only targeted medications are for depression, whose medications are intended for once daily use and are randomized to proceed with usual care"
            }, 
            {
                "arm_group_label": "1 med \u22652x daily use, all but depression, Rx Timer Cap", 
                "arm_group_type": "Experimental", 
                "description": "Individuals who are suboptimally adherent to targeted therapies except antidepressants, who have at least one medication that is intended for use more than once daily and are randomized to receive the Rx Timer Cap"
            }, 
            {
                "arm_group_label": "\u22651 med \u22652x daily use, only depression, Rx Timer Cap", 
                "arm_group_type": "Experimental", 
                "description": "Individuals whose only targeted medications are for depression and who are suboptimally adherent to this therapy, for whom at least one medication is intended for use more than once daily and are randomized to receive the Rx Timer Cap"
            }, 
            {
                "arm_group_label": "\u22651 med \u22652x daily use, all but depression, PillMinder", 
                "arm_group_type": "Experimental", 
                "description": "Individuals who are suboptimally adherent to targeted therapies except antidepressants, who have at least one medication that is intended for use more than once daily and are randomized to receive the PillMinder"
            }, 
            {
                "arm_group_label": "\u22651 med \u22652x daily use, only depression, PillMinder", 
                "arm_group_type": "Experimental", 
                "description": "Individuals whose only targeted medications are for depression and who are suboptimally adherent to this therapy, for whom at least one medication is intended for use more than once daily and are randomized to receive the PillMinder"
            }, 
            {
                "arm_group_label": "\u22651 med \u22652x daily use, all but depression, Control", 
                "arm_group_type": "No Intervention", 
                "description": "Individuals who are suboptimally adherent to targeted therapies except antidepressants, who have at least one medication that is intended for use more than once daily and are randomized to proceed with usual care"
            }, 
            {
                "arm_group_label": "\u22651 med \u22652x daily use, only depression, Control", 
                "arm_group_type": "No Intervention", 
                "description": "Individuals whose only targeted medications are for depression and who are suboptimally adherent to this therapy, for whom at least one medication is intended for use more than once daily and are randomized to proceed with usual care"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to determine whether adherence to oral maintenance medications\n      differs for patients randomized to receive a Take-N-Slide, a RxTimerCap, a PillMinder, or\n      none of these devices, with the hypothesis that low-touch devices improve adherence over\n      control and that the increase in adherence is agnostic across devices."
        }, 
        "brief_title": "Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Cardiovascular Disease", 
            "Depression", 
            "Diabetes", 
            "Mental Health Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Breast Neoplasms", 
                "Cardiovascular Diseases", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Given that the Take-N-Slide device only has a Yes/No toggle for each day of the week and can\n      therefore only be used once per day, the study population will be stratified into two\n      separate trials based on the frequency with which the study participants' medications are\n      (or could possibly be) taken. Patients who are on a medication that is used more than once\n      daily will be included in Trial 2, which evaluates only the RxTimer Cap and the PillMinder.\n      Within each trial, all patients meeting the inclusion criteria within each trial will be\n      randomized into two blocks, the first of which will consist of all patients suboptimally\n      adherent to all targeted medications excluding antidepressants, and the second of all\n      patients whose only targeted medications are for depression and who are suboptimally\n      adherent to this therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have 1 to 3 oral maintenance medications in pill or capsule form and filled via mail\n             order or at a retail pharmacy within 12 months prior to being identified as being\n             eligible for the study, at least one of which must be intended for either:\n\n          -  A chronic condition (defined as breast cancer, cardiovascular disease, diabetes or a\n             major mental health condition); OR\n\n          -  Depression.\n\n          -  Be suboptimally adherent to all of the targeted drug classes, defined as a Medication\n             Possession Ratio (see Outcomes and Analysis section below for definition) of 30% to\n             less than 80% during the 12 months preceding identification of study eligibility,\n             except where noted below;\n\n          -  For patients taking antidepressants in addition to other targeted medications,\n             patients need only be suboptimally adherent to their non-antidepressant medications;.\n\n          -  Eligible for pharmacy benefits during the 12 months prior to being identified as\n             being eligible for the study and expected to be eligible for pharmacy benefits\n             through the end of the evaluation period.\n\n        Exclusion Criteria:\n\n          -  Enrolled in Ready Fill at Mail (a pharmacy benefit program whereby members elect to\n             have medications shipped automatically to them at the time of refill due date or\n             prescription renewal)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015806", 
            "org_study_id": "2013-P-00009085"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "All meds 1x daily use, all but depression, Rx Timer Cap", 
                    "All meds 1x daily use, only depression, Rx Timer Cap", 
                    "1 med \u22652x daily use, all but depression, Rx Timer Cap", 
                    "\u22651 med \u22652x daily use, only depression, Rx Timer Cap"
                ], 
                "description": "The RxTimer Cap is a pill bottle with a digital timer on the cap that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.", 
                "intervention_name": "Rx Timer Cap", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "All meds 1x daily use, all but depression, PillMinder", 
                    "All meds 1x daily use, only depression, PillMinder", 
                    "\u22651 med \u22652x daily use, all but depression, PillMinder", 
                    "\u22651 med \u22652x daily use, only depression, PillMinder"
                ], 
                "description": "The pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.", 
                "intervention_name": "PillMinder", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "All meds 1x daily use, all but depression, Take-N-Slide", 
                    "All meds 1x daily use, only depression, Take-N-Slide"
                ], 
                "description": "The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.", 
                "intervention_name": "Take-N-Slide", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Quality improvement", 
            "Randomized controlled trial", 
            "Medication adherence", 
            "RxTimer Cap", 
            "PillMinder", 
            "Take-N-Slide", 
            "Low-touch devices", 
            "Medication management"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "Charmaine.Girdish@caremark.com", 
                "last_name": "Charmaine Girdish", 
                "phone": "480-707-6645"
            }, 
            "facility": {
                "address": {
                    "city": "Woonsocket", 
                    "country": "United States", 
                    "state": "Rhode Island", 
                    "zip": "02895"
                }, 
                "name": "CVS Caremark"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "14", 
        "official_title": "Assessing the Impact of Low-Touch Devices on Medication Adherence", 
        "other_outcome": {
            "description": "Medication adherence will be calculated using Medication Possession Ratios (MPR) for antidepressants, and assessed using administrative pharmacy claims", 
            "measure": "Average medication adherence for patients whose only targeted medications are for depression and who are suboptimally adherent to this therapy", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital/Harvard Medical School", 
            "last_name": "Niteesh K Choudhry, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Optimal adherence to medications is defined as a Medication Possession Ratio (MPR) equal to or greater than 0.80 and assessed using administrative pharmacy claims", 
            "measure": "Optimal medication adherence among patients suboptimally adherent to targeted medications excluding antidepressants", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015806"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Niteesh K. Choudhry, MD, PhD", 
            "investigator_title": "Associate Professor, Harvard Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Medication adherence will be calculated using Medication Possession Ratios (MPR) for each of the targeted therapies the patient is on, and assessed using administrative pharmacy claims", 
            "measure": "Average adherence among patients suboptimally adherent to targeted medications including those intended to treat depression", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "CVS Caremark", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}